HIGHLIGHTS
- who: Elisa Conde and colleagues from the Molecular Epidemiology and Predictive Tumor Markers Group, Alcalá University, Ramón y Cajal Health, IRYCIS, Madrid, Spain have published the article: Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study, in the Journal: (JOURNAL)
- what: This study aimed to identify useful biomarkers to stratify patients suitable for regorafenib first-line treatment and to unveil potential mechanisms responsible for the beneficial effects of this treatment in fragile mCRC patients. To integrate the data obtained in this study, the association between the miRNA . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.